한글목차

올파시란(구 AMG 890)은 심혈관계 질환의 위험 증가와 관련된 Lp(a)의 주요 성분인 아포지단백(a)의 체내 생성을 감소시키도록 설계된 저분자 간섭 RNA입니다.

지단백(a)(Lp(a)) 수치(>150nmol/L)가 높고 죽상동맥경화성 심혈관질환(ASCVD) 병력이 있는 성인을 대상으로 한 올파시란의 임상 II상 OCEAN(a)-DOSE 시험의 치료 종료 데이터가 지난 11월 미국심장협회(AHA) 학술 학술대회 2022의 Late-Breaking Science 세션에서 발표되었으며, 동시에 New England Journal of Medicine 저널에 게재되었습니다. 현재 임상 3상 시험이 진행 중이며, 2027년까지 데이터를 얻을 수 있을 것으로 예상됩니다.

앞으로 몇 년동안 심근경색증 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 질환을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 올파시란의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 다른 심근경색 치료제들도 올파시란과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시될 경우 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 심근경색 치료제 올파시란 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 심근경색 올파시란 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 올파시란 시장 평가

• 심근경색 치료제 올파시란 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 심근경색 치료제 올파시란 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"Olpasiran Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about olpasiran for myocardial infarction in the seven major markets. A detailed picture of the olpasiran for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the olpasiran for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the olpasiran market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

Olpasiran (formerly AMG 890) is a small interfering RNA designed to lower the body's production of apolipoprotein (a), a key component of Lp (a) that has been associated with an increased risk of cardiovascular events.

In November 2022, the company presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran in adults with elevated lipoprotein (a) [Lp (a)] levels (>150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD) during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2022, and simultaneously published in the New England Journal of Medicine. The company is currently conducting a Phase III trial with data expected by 2027.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the olpasiran description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on olpasiran regulatory milestones and other development activities have been provided in this report.
• The report also highlights the olpasiran research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around olpasiran.
• The report contains forecasted sales of olpasiran for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for olpasiran in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Olpasiran Analytical Perspective by DelveInsight

• In-depth Olpasiran Market Assessment

This report provides a detailed market assessment of olpasiran for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

• Olpasiran Clinical Assessment

The report provides the clinical trials information of olpasiran for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence olpasiran dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to olpasiran and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of olpasiran in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of olpasiran from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the olpasiran in myocardial infarction.

Key Questions:

• What is the product type, route of administration and mechanism of action of olpasiran?
• What is the clinical trial status of the study related to olpasiran in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the olpasiran development?
• What are the key designations that have been granted to olpasiran for myocardial infarction?
• What is the forecasted market scenario of olpasiran for myocardial infarction?
• What are the forecasted sales of olpasiran in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to olpasiran for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

Table of Contents

1. Report Introduction

2. Olpasiran Overview in myocardial infarction

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Olpasiran Market Assessment

• 5.1. Market Outlook of Olpasiran in myocardial infarction
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Olpasiran in the 7MM for myocardial infarction
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Olpasiran in the United States for myocardial infarction
  • 5.3.2. Market Size of Olpasiran in Germany for myocardial infarction
  • 5.3.3. Market Size of Olpasiran in France for myocardial infarction
  • 5.3.4. Market Size of Olpasiran in Italy for myocardial infarction
  • 5.3.5. Market Size of Olpasiran in Spain for myocardial infarction
  • 5.3.6. Market Size of Olpasiran in the United Kingdom for myocardial infarction
  • 5.3.7. Market Size of Olpasiran in Japan for myocardial infarction

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options